|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointments of Certain Officers; Compensatory Arrangements of Certain Officers.
|
GYRE THERAPEUTICS, INC.
|
||
Date: December 15, 2023
|
By:
|
/s/ Ruoyu Chen
|
Name:
|
Ruoyu Chen
|
|
Title:
|
Chief Financial Officer
|
Document and Entity Information |
Dec. 11, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 11, 2023 |
Entity File Number | 000-51173 |
Entity Registrant Name | Gyre Therapeutics, Inc. |
Entity Central Index Key | 0001124105 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 56-2020050 |
Entity Address, Address Line One | 12770 High Bluff Drive |
Entity Address, Address Line Two | Suite 150 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92130 |
City Area Code | 619 |
Local Phone Number | 949-3681 |
Title of 12(b) Security | Common Stock |
Trading Symbol | GYRE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
T7L^; &PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M " "S@H]799!YDAD! #/ P $P @ &K$@ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #U$P !
end
RHY_U=3_ 102P,$%
M @ LX*/5Y>*NQS $P( L !?
NF)WH[) &W0(*RVK!U_$,;-"FEC@]#@L
M[EE.Y'LTIB)TDY!OH1X".UI6#B\VVY]W$ACP DFQ$@$[5LP=9CF@IICG"Q
M']9S7<:BV/)B>QL/(O*B-GAP]CV3U5_-7SCO'G[E5.YKJ8 $52Y7Z4P:/%*C
MQ( -$V(.94!AH M ,EK4AQD;,[I/ RIYD+Q^9Z>%7ZJEUA=UW9_8QT/!/ND#
M.CH>*PF6#/,DL;PEL#H#^FH WB4N,(9=&5&FF0><.W X(9I0TY;9LSB5I0"RZWNZ)F/@+@D+
MZ*,=Z Q84J,Z6N@ _@&0 V7PKJUBF([!E02W$>RFHBDNWL*5GD>T6)2 )5KI%7C-W4RV$UD7-G+PJ9&Y*YRP'M(P-_QM
M\%^9O"K#!2ZW.^2UDB/\:"$CXE
Z .J%%3_(AR85*IV7NMLI"(S+T=:D5
MQ+3Y7LK;R]__V5H21;U*/\TED =BII9^7E%)G\34*"3-]]ID:,-I*( ]T#M0
M^4S-"]@\5=& _6N2FB1"852-9@V=1- ;K&O6YYVT